Mirati Therapeutics, Inc. (MRTX)
After hours: 04:01PM EDT
- Zacks
Mirati's (MRTX) Adagrasib Gets Breakthrough Therapy Status
Mirati (MRTX) is developing adagrasib as a potential treatment for patients suffering from non-small cell lung cancer with KRAS mutation. An NDA is expected to be filed in the second half of 2021.
- Benzinga
Mirati's KRAS Inhibitor Receives FDA Breakthrough Tag For Lung Cancer Harboring KRAS Mutation
The FDA has granted Breakthrough Therapy designation to Mirati Therapeutics Inc's (NASDAQ: MRTX) adagrasib in non-small cell lung cancer (NSCLC) patients with the KRAS-G12C mutation. The decision was based on preliminary results from the Phase 1/2 KRYSTAL-01 trial in patients with advanced NSCLC whose cancer had progressed following prior treatment with immunotherapy or chemotherapy. According to data presented in October, 45% of patients saw an objective response. Those numbers come from a pool
- PR Newswire
Mirati Therapeutics' Adagrasib Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Patients with Advanced Non-Small Cell Lung Cancer Harboring the KRAS G12C Mutation
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to adagrasib for the potential treatment of patients with non-small cell lung cancer (NSCLC) who harbor the KRASG12C mutation following prior systemic therapy.
